Possible induction of renal dysfunction in patients with lecithin:cholesterol acyltransferase deficiency by oxidized phosphatidylcholine in glomeruli

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 19, Issue 3, 1999, Pages 794-801

  Jimi, Shiro ^a   Uesugi, Noriko ^a   Saku, Keijiro ^a   Itabe, Hiroyuki ^b   Zhang, Bo ^a   Arakawa, Kikuo ^a   Takebayashi, Shigeo ^a  

^a FUKUOKA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TEIKYO UNIVERSITY   (Japan)

Author keywords

Kidney; Lecithin:cholesterol acyltransferase deficiency; Modified LDL; Oxidized phosphatidylcholine

Indexed keywords

HIGH DENSITY LIPOPROTEIN; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE;

ADULT; ANEMIA; ARTICLE; CLINICAL ARTICLE; CORNEA OPACITY; ELECTRON MICROSCOPY; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HYPOLIPOPROTEINEMIA; IMMUNOHISTOCHEMISTRY; KIDNEY DISEASE; MALE; PRIORITY JOURNAL;

EID: 0032975173     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.19.3.794     Document Type: Article

References (52)

1. Glomset JA, Assmann G, Gjone E, Norum KR. Lecithin:cholesterol acyltransferase deficiency and Fish-eye disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease. New York, NY: McGraw-Hill Inc; 1995;2:1933-1951.
2. McLean J, Wion K, Drayna D, Fielding C, Lawn R. Human lecithin-cholesterol acyltransferase gene: complete gene sequence and sites of expression. Nucleic Acids Res. 1986;14:9397-9406.
3. Gotoda T, Yamada N, Murase T, Sakuma M, Murayama N, Shimano H, Kozaki K, Albers JJ, Yazaki Y, Akanuma Y. Differential phenotypic expression by three mutant alleles in familial lecithin:cholesterol acyltransferase deficiency. Lancet. 1991;338:778-781.
4. Kuivenhoven JA, Pritchard H, Hill J, Frohlich J, Assmann G, Kastelein J. The molecular pathology of lecithin:cholesterol acyltransferase (LCAT) deficiency syndromes. J Lipid Res. 1997;38:191-205.
5. Bujo H, Kusunoki J, Ogasawara M, Yamamoto T, Ohta Y, Shimada T, Saito Y, Yoshida S. Molecular defect in familial lecithin:cholesterol acyltransferase (LCAT) deficiency: a single nucleotide insertion in LCAT gene causes a complete deficient type of the disease. Biochem Biophys Res Commun. 1991;181:933-940.
6. 344Ser). J Lipid Res. 1995;36:2329-2343.
7. Miettinen H, Gylling H, Ulmanen I, Miettinen TA, Kontula K. Two different allelic mutations in a Finnish family with lecithin cholesterol acyltransferase deficiency. Arterioscler Thromb Vasc Biol. 1995;15: 460-467.
8. 156-asn). J Lipid Res. 1993;34:49-58.
9. Funke H, von Eckardstein A, Pritchard PH, Hornby AE, Wiebusch H, Motti C, Hayden MR, Dachet C, Jacotot B, Gerdes U, Faergeman O, Albers JJ, Colleoni M, Catapano A, Frohlich J, Assmann G. Genetic and phenotypic heterogeneity in familial lecithin:cholesterol acyltransferase (LCAT) deficiency. J Clin Invest. 1993;91:677-683.
10. Midorikawa K, Katsuaki S, Abe K, Kinoshita E, Nomura G, Toshima H, Morimatsu M, Nanbu S. Familial LCAT deficiency, a case report. J Jpn Atheroscler Soc. 1983;11:1215-1220. [in Japanese].
11. Egami J, Ishizaki K, Inoue T, Majima K, Kinoshita E, Nimura K, Midorikawa K, Morimatsu M. A case of LCAT deficiency with nephrotic syndrome performed with two renal biopsies within six years. Jin-totoseki. 1994;37:811-815. [in Japanese].
12. Takata K, Kajiwara G, Horiuchi I, Watanabe T, Tokumo H, Hirata Y. A new case of familial lecithin:cholesterol acyltransferase (LCAT) deficiency. Jpn J Med. 1989;28:765-771.
13. Norum KR, Glomset JA, Nichols AV, Forte T, Alberts J, King WC, Mitchell CD, Applegate KR, Gong EL, Cabana V. Plasma lipoproteins in familial lecithin:cholesterol acyltransferase deficiency: effects of incubation with lecithin:cholesterol acyltransferase in vitro. Scand J Clin Lab Invest. 1975;35/142(suppl):31-35.
14. Glomset JA, Mitchell CD, King WC, Applegate KR, Forte T, Norum KR, Gjone E. In vitro effects of lecithin:cholesterol acyltransferase on apolipoprotein distribution in familial lecithin:cholesterol acyltransferase deficiency. Ann N Y Acad Sci. 1980;348:224-243.
15. Ohta T, Hattori S, Nakamura R, Horiuchi S, Frolich S, Takata K, Ikeda Y, Saito Y, Matsuda I. Characterization of subspecies of apolipoprotein A-I-containing lipoprotein in homozygotes for familial lecithin:cholesterol acyltransferase deficiency. Arterioscler Thromb Vasc Biol. 1994;14: 1137-1145.
16. Stokke KT, Bjerve KS, Blomhoff JP, Oystese B, Flatmark A, Norum KR, Gjone E. Lecithin:cholesterol acyltransferase deficiency: study on lipid composition and morphology of tissue. Scand J Clin Lab Invest. 1974; 33/137(suppl):93-100.
17. Gjone E. Familial lecithin:cholesterol acyltransferase (LCAT) deficiency: an updated review. Ophthalmic Paediatr Genet. 1988;9:167-169.
18. Godin DV, Gray GR, Frohlich J. Erythrocyte membrane alterations in lecithin:cholesterol acyltransferase deficiency. Scand J Clin Lab Invest. 1978;150(suppl): 162-167.
19. Murayama N, Asano Y, Hosoda S, Maesawa M, Saito M, Takaku F, Sugihara T, Miyashima K, Yawata Y. Decreased sodium influx and abnormal red cell membrane lipids in a patient with familial plasma lecithin:cholesterol acyltransferase deficiency. Am J Hematol. 1984;16: 129-137.
20. Rajaram OV, Barter PJ. Increases in particle size of high-density lipoproteins induced by purified lecithin:cholesterol acyltransferase: effect of low-density lipoproteins. Biochim Biophys Acta. 1986;877: 406-416.
21. Steinberg D. The rediscovery of high density lipoprotein: a negative factor in atherosclerosis. Eur J Clin Invest. 1978;8:107-109.
22. Badimon JJ, Fuster V, Badimon L. Role of high density lipoproteins in the regression of atherosclerosis. Circulation. 1992;86(suppl III):III-86-III-94.
23. Davidson WS, Gillotte KL, Lundkatz S, Jonson WJ, Rothblat GH, Phillips MC. The effect of high density lipoprotein phospholipid acyl chain composition on the efflux of cellular free cholesterol. J Biol Chem. 1995;270:5882-5890.
24. Subbaiah PV, Liu M. Disparate effects of oxidation on plasma acyltransferase activities: inhibition of cholesterol esterification but stimulation of trans esterification of oxidized phospholipid. Biochim Biophys Acta. 1996;1301:115-126.
25. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;362:801-809.
26. Steinberg D. Low density lipoprotein oxidation and its pathobiological significance. J Biol Chem. 1997;272:20963-20966.
27. Jimi S, Saku K, Uesugi N, Sakata N, Takebayashi S. Oxidized low density lipoprotein stimulates collagen production in cultured arterial smooth muscle cells. Atherosclerosis. 1995;116:15-26.
28. Ylä-Herttuala S, Palinski W, Rosenfeld ME, Parthasarathy S, Carew TE, Butler S, Witztum JL, Steinberg D. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest. 1989;84:1086-1095.
29. Itabe H, Takeshima E, Iwasaki H, Kimura J, Yoshida Y, Imanaka T, Takano T. A monoclonal antibody against oxidized lipoprotein recognizes foam cells in atherosclerotic lesions: complex formation of oxidized phosphatidylcholines and polypeptides. J Biol Chem. 1994;269: 15274-15279.
30. Aragane K, Ishigami M, Funahashi T, Yamashita S, Takemura Y, Matsuzawa Y, Kano H, Muchi H, Kitajima K. A new case of LCAT deficiency and his genetic analysis. Japan Atherosclerosis Society Winter Meeting Abstract Book. Tokyo, Japan: Jap J Atherosclerosis. 1995; 23:180.
31. Liu K, Saku K, Bai H, Liu R, Arakawa K, Jimi S, Uesugi N, Takebayashi S, Hiroki T, Takata K, Kajiyama G. Re-evaluation from the gene assay of the patient with LCAT deficiency. Japan Atherosclerosis Society Winter Meeting Abstract Book. Tokyo, Japan: Jap J Atherosclerosis. 1996; 24:285.
32. Allain CC, Poon LS, Chan CS, Richmond W, Fu PC. Enzymatic determination of total serum cholesterol. Clin Chem. 1974;20:470-475.
33. Bucolo G, David H. Quantitative determination of serum triglycerides by the use of enzymes. Clin Chem. 1973;19:476-482.
34. 2+ and an anion-exchange resin. Clin Chem. 1978;24: 1504-1508.
35. Nagasaki T, Akanuma Y. A new colorimetric method for the determination of plasma lecithin-cholesterol acyltransferase activity. Clin Chim Acta. 1977;75:371-375.
36. Albers JJ, Adolphson JL, Chen CH. Radioimmunoassay of human plasma lecithin:cholesterol acyltransferase. J Clin Invest. 1981;67:141-148.
37. Higuchi R. Simple and rapid preparation of sample for PCR. In: Erich HA, ed. PCR Technology: Principal and Applications for DNA Amplification. New York, NY: Stockton Press; 1989:31-39.
38. Itabe H, Yamamoto H, Imanaka T, Shimamura K, Uchiyama H, Kimura J, Sanaka T, Hata Y, Takanao T. Sensitive detection of oxidatively modified low density lipoprotein using a monoclonal antibody. J Lipid Res. 1996;37:45-53.
39. SAS User's Guide: Basics. version 5 ed. Cary, NC: SAS Institute Inc; 1985:861-1192.
40. SAS/STAT User's Guide, version 6, 4th edition. Cary, NC: SAS Institute Inc; 1990;2:891-1456.
41. Sevanian A, Bittolo-Bon G, Cazzolato G, Hodis H, Hwang J, Zamburlini A, Mariorino M, Ursini F. LDL is a lipid hydroperoxide-enriched circulating lipoprotein. J Lipid Res. 1997;38:419-428.
42. Koster H, Savoldelli M, Dumon MF, Dubourg L, Clerc M, Pouliquen Y. A Fish-eye disease-like familial condition with massive corneal clouding and dyslipoproteinemia. Cornea. 1992;11:452-464.
43. Carlson LA, Philipson B. Fish-eye disease: a new familial condition with massive corneal opacities and dyslipoproteinemia. Lancet. 1979;2: 922-924.
44. Carlson LA, Holmquist L. Evidence for deficiency of high density Hpoprotein lecithin:cholesterol acyltransferase activity (a -LCAT) in Fish-eye disease. Acta Med Scand. 1985;218:189-196.
45. Sakai N, Vaisman BL, Koch CA, Paiz JA, Brewer HB Jr, Santamarina-Fojo S. Analysis of aortic atherosclerosis and glomerulosclerosis in LCAT knockout mice. Circulation. 1997;96(suppl I):I-229. Abstract.
46. Deleted in proof.
47. Parthasarathy S, Barnett J, Fong G. High-density lipoprotein inhibits the oxidative modification of low density lipoprotein. Biochim Biophys Acta. 1990;1044:275-283.
48. Matsuda Y, Hihara K, Inoue N, Suematsu M, Kawashima S, Akita H, Yokoyama M. High density lipoprotein reverses inhibitory effect of oxidized low density lipoprotein on the endothelial-dependent arterial relaxation. Circ Res. 1993;72:1103-1109.
49. Maziere JC, Myara I, Salmon S, Auclair M, Haigle J, Santus R, Maziere C. Copper- and malondialdehyde-induced modification of high density lipoprotein and parallel loss of lecithin:cholesterol acyltransferase activation. Atherosclerosis. 1993;104:213-219.
50. Bielicki JK, Forte TM, McCall MR. Minimally oxidized LDL is a potent inhibitor of lecithin:cholesterol acyltransferase activity. J Lipid Res. 1996;37:1012-1021.
51. Sevanian A, Hwang J, Hodis H, Cazzolato G, Avogaro P, Bittolo-Bon G. Contribution of an in vivo oxidized LDL to LDL oxidation and its association with dense LDL subpopulations. Arterioscler Thromb Vasc Biol. 1996;16:784-793.
52. Ohta T, Saku K, Takata K, Nagata N, Maung KK, Matsuda I. Fractional esterification rate of cholesterol in high density lipoprotein (HDL) can predict the particle size of low density lipoprotein and HDL in patients with coronary heart disease. Atherosclerosis. 1997;135:205-212.